The Quadruple Marker Test is a second-trimester screening test performed between 15-20 weeks of pregnancy to evaluate the risk of chromosomal abnormalities, genetic defects, and neural tube defects in the fetus. This test measures four key substances in the mother's blood: Human Chorionic Gonadotropin (hCG): A hormone produced by the placenta. Alpha-Fetoprotein (AFP): A protein released by the developing fetus. Inhibin A: A hormone secreted by the placenta. Unconjugated Estriol (UE): A hormone produced by the fetus's liver and placenta. The test provides risk estimates but does not confirm the presence of abnormalities.

Low-Risk Result: Indicates a reduced likelihood of chromosomal or neural tube defects. High-Risk Result: Suggests a higher chance of conditions like Down Syndrome, Edward’s Syndrome, or neural tube defects. Further diagnostic tests like amniocentesis may be recommended. Conditions Monitored: Down Syndrome (Trisomy 21) Edward’s Syndrome (Trisomy 18) Neural tube defects (e.g., spina bifida) Other genetic abnormalities

Test price for other cities